From: Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer
N (%) | |
---|---|
Age | |
≥50 | 93 (72.1) |
<50 | 36 (27.9) |
Median age (range) | 56 (31–84) |
PS | |
0 | 83 (64.3) |
1 | 39 (30.2) |
2 | 7 (5.4) |
Intrinsic subtype | |
Luminal | 85 (66.2) |
Luminal-HER2 | 24 (18.6) |
HER2 | 10 (7.6) |
Triple negative | 10 (7.6) |
Metastasis site with bone | |
Brain | 3 (2.3) |
Liver | 13 (10.1) |
Lung | 9 (7.0) |
Zoledronic acid and/or denosumab use | 121 (95.3) |
Other bisphosphonate use | 5 (3.9) |
Median BSI (%) | 1.08 |
Inter quartile range (%) | 0.50–3.23 |
SRE | 33 (25.6) |
Surgical therapy received | 5 (3.9) |
Radiation therapy received | 28 (21.7) |